AlphaRose Therapeutics Acquires Alpha Anomeric SA

April 29, 2025

AlphaRose Therapeutics has acquired Alpha Anomeric SA, a Paris-based developer of the abcDNA oligonucleotide chemistry platform. The acquisition brings a proprietary antisense oligonucleotide chemistry into AlphaRose's portfolio and establishes a European presence to support global development of its neurogenetic and rare-disease programs. Terms were not disclosed.

Buyers
AlphaRose Therapeutics
Targets
Alpha Anomeric SA
Industry
Biotechnology
Location
France
Transaction Type
Buyout

Explore More

Related Acquisitions

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.